RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
The presented data include results with novel self-delivering (sd-rxRNA™) RNAi compounds, which do not require an additional delivery vehicle to enter cells. The data show significantly improved pharmacological properties of these molecules, with applicability in a broad range of therapeutic applications.
“We are excited about the progress we are making in our sd-rxRNA™ research efforts,” said Tod Woolf, Ph.D. President and CEO of RXi Pharmaceuticals. “A key highlight from our presentation was that recently obtained data with our proprietary sd-rxRNA™ markedly improves the delivery of systemically and locally administered RNAi compounds. RXi and our collaborators in RNAi consider advances in the delivery to be the most important factor for the successful commercialization of RNAi therapeutics. ”
RXi’s therapeutic platform leverages its Next Generation rxRNA™ compounds and advanced delivery technologies to enable its internal programs and external collaborations. This provides RXi with multiple opportunities for the potential development of a sustainable pipeline of RNAi based products for unmet medical needs.
Key findings and highlights from the event include the following: